D.A. Davidson & CO. Grows Position in Guardant Health, Inc. (NASDAQ:GH)

D.A. Davidson & CO. boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 72.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 42,380 shares of the company’s stock after buying an additional 17,755 shares during the quarter. D.A. Davidson & CO.’s holdings in Guardant Health were worth $1,295,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. International Assets Investment Management LLC boosted its holdings in Guardant Health by 2,193.9% in the third quarter. International Assets Investment Management LLC now owns 10,208 shares of the company’s stock valued at $2,340,000 after purchasing an additional 9,763 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock valued at $102,000 after acquiring an additional 796 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Guardant Health by 168.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after acquiring an additional 2,153 shares during the period. abrdn plc boosted its holdings in shares of Guardant Health by 47.9% in the third quarter. abrdn plc now owns 552,473 shares of the company’s stock valued at $12,674,000 after acquiring an additional 178,882 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Guardant Health by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 23,661 shares of the company’s stock valued at $543,000 after acquiring an additional 9,283 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 2,768 shares of company stock valued at $98,798 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on GH shares. Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Raymond James reaffirmed an “outperform” rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a report on Friday. Sanford C. Bernstein decreased their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group increased their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday. Eighteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health presently has an average rating of “Buy” and an average price target of $44.78.

Guardant Health Stock Down 9.6 %

NASDAQ:GH opened at $42.87 on Friday. The company has a market capitalization of $5.30 billion, a PE ratio of -12.04 and a beta of 1.32. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89. The stock has a fifty day simple moving average of $40.19 and a 200-day simple moving average of $31.59.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.